SG10201403200RA - Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products - Google Patents

Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Info

Publication number
SG10201403200RA
SG10201403200RA SG10201403200RA SG10201403200RA SG10201403200RA SG 10201403200R A SG10201403200R A SG 10201403200RA SG 10201403200R A SG10201403200R A SG 10201403200RA SG 10201403200R A SG10201403200R A SG 10201403200RA SG 10201403200R A SG10201403200R A SG 10201403200RA
Authority
SG
Singapore
Prior art keywords
nash
methods
alcoholic steatohepatitis
treating non
cysteamine products
Prior art date
Application number
SG10201403200RA
Other languages
English (en)
Inventor
Ranjan Dohil
Jerry Schneider
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201403200R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of SG10201403200RA publication Critical patent/SG10201403200RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG10201403200RA 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products SG10201403200RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US8539708P 2008-07-31 2008-07-31

Publications (1)

Publication Number Publication Date
SG10201403200RA true SG10201403200RA (en) 2014-10-30

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201403200RA SG10201403200RA (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Country Status (26)

Country Link
US (5) US7994226B2 (fr)
EP (2) EP2636404B1 (fr)
JP (3) JP5583022B2 (fr)
KR (1) KR20100091219A (fr)
CN (2) CN101932238B (fr)
AR (1) AR069500A1 (fr)
AU (1) AU2008329628B2 (fr)
BR (1) BRPI0819690B8 (fr)
CA (1) CA2706768C (fr)
CL (1) CL2008003582A1 (fr)
CY (1) CY1114126T1 (fr)
DK (1) DK2214480T3 (fr)
ES (1) ES2417179T3 (fr)
HK (1) HK1141945A1 (fr)
HR (1) HRP20130590T1 (fr)
IL (2) IL205909B (fr)
MX (2) MX360827B (fr)
MY (1) MY156316A (fr)
NZ (1) NZ585732A (fr)
PL (1) PL2214480T3 (fr)
PT (1) PT2214480E (fr)
RU (1) RU2498795C2 (fr)
SG (1) SG10201403200RA (fr)
TW (2) TWI478710B (fr)
WO (1) WO2009070781A1 (fr)
ZA (1) ZA201003670B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2535044T (pt) 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
CN101932238B (zh) 2007-11-30 2015-04-08 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法
CA2798735A1 (fr) * 2010-05-19 2011-11-24 Haruki Shibata Agent prophylactique et/ou therapeutique pour une steatohepatite non alcoolique
SG185754A1 (en) * 2010-06-08 2012-12-28 Mahesh Kandula Cysteamine derivatives and their use in the treatment of nash
US20140187594A1 (en) * 2010-07-28 2014-07-03 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
WO2014045293A1 (fr) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Amides d'acides gras comportant un groupe cystéamine ou un groupe cystéamine acétylé et leurs utilisations
BR112014006220A2 (pt) 2011-09-16 2017-04-11 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
WO2013062544A1 (fr) * 2011-10-26 2013-05-02 Seattle Children's Research Institute Cystéamine dans le traitement d'une maladie fibreuse
SG10201800159QA (en) * 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
US20150086627A1 (en) * 2012-03-29 2015-03-26 Halo Therapeutics, Llc. Dosage forms of halofuginone and methods of use
BR112014030534A2 (pt) 2012-06-06 2017-06-27 Galectin Therapeutics Inc composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CN106659722A (zh) * 2014-04-18 2017-05-10 株式会社Lg生命科学 用于预防或治疗脂肪肝疾病的组合物
EP3266461A4 (fr) * 2015-03-03 2018-11-14 KOHJIN Life Sciences Co., Ltd. Composition pour l'amélioration ou la prévention de la stéatose hépatique non alcoolique
ES2770113T3 (es) 2015-07-02 2020-06-30 Horizon Orphan Llc Análogos de la cisteamina resistentes a la ADO y sus usos
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
JP7418958B2 (ja) * 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3634411B1 (fr) * 2017-06-08 2023-09-20 N-Gene Research Laboratories Inc. Méthodes de traitement de la stéatohépatite non alcoolique et de prévention d'un carcinome hépatocellulaire induit par la stéatohépatite non alcoolique
US10632092B2 (en) 2017-08-30 2020-04-28 First Fruits Business Ministry, Llc Composition for and method to increase serum adiponectin and reduce body fat
CN111683684B (zh) * 2017-09-20 2024-07-02 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
EP3946298A4 (fr) 2019-03-26 2023-01-25 The Regents of the University of California Composés de type amino-thyol et amino-disulfide substitués et leurs utilisations
JP2022542840A (ja) * 2019-07-19 2022-10-07 フィルトリシン， インコーポレイテッド がん処置および代謝介入療法および他の使用のための組成物、方法、キットならびにシステム
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
CA2236344A1 (fr) * 1998-04-30 1999-10-30 Hemosol Inc. Complexes hemoglobine-haptoglobine
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU2001237080A1 (en) * 2000-02-14 2001-08-20 Len Booysen Stabilizer unit
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
EP1461033B1 (fr) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methodes et compositions permettant de diminuer les effets indesirables de la chimiotherapie
KR20040078663A (ko) * 2002-01-04 2004-09-10 사운드 파마슈티칼스 인코퍼레이티드 난청의 치료 방법
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
WO2005049002A1 (fr) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Produits et procedes permettant d'ameliorer le metabolisme de l'alcool et d'attenuer les effets du syndrome appele « gueule de bois »
CN101897970A (zh) 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CA2565250C (fr) * 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines pour le traitement des complications de l'hypercholesterolimie et du diabete
AP2007004084A0 (en) 2005-01-05 2007-08-31 Fisher Cormack & Botha Taurine synthesis production and utility as a medicine
PL1879599T3 (pl) * 2005-04-20 2014-03-31 Hutchinson Fred Cancer Res Sposoby, kompozycje i wyroby do zwiększania przeżywalności komórek, tkanek, narządów i organizmów
BRPI0620255A2 (pt) * 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
PT2535044T (pt) * 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
WO2007121545A1 (fr) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp Compositions contenant des s-nitrosothiols et utilisation de ces compositions
AU2007248483A1 (en) 2006-05-03 2007-11-15 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
WO2008093764A1 (fr) 2007-02-02 2008-08-07 Kaneka Corporation Composition pour la prévention ou le traitement du diabète
CN101932238B (zh) 2007-11-30 2015-04-08 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法

Also Published As

Publication number Publication date
AU2008329628A1 (en) 2009-06-04
MY156316A (en) 2016-02-11
US20160143865A1 (en) 2016-05-26
IL205909A0 (en) 2010-11-30
US9149448B2 (en) 2015-10-06
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
HRP20130590T1 (en) 2013-08-31
EP2214480B1 (fr) 2013-03-27
TW200927093A (en) 2009-07-01
RU2010126631A (ru) 2012-01-10
WO2009070781A1 (fr) 2009-06-04
BRPI0819690B8 (pt) 2021-05-25
BRPI0819690A2 (pt) 2014-10-07
BRPI0819690B1 (pt) 2019-07-30
US9511038B2 (en) 2016-12-06
US20130183351A1 (en) 2013-07-18
CY1114126T1 (el) 2016-07-27
CA2706768C (fr) 2016-06-28
TW201513855A (zh) 2015-04-16
MX360827B (es) 2018-11-16
JP2011505375A (ja) 2011-02-24
PT2214480E (pt) 2013-07-23
DK2214480T3 (da) 2013-07-08
ZA201003670B (en) 2011-08-31
US7994226B2 (en) 2011-08-09
CA2706768A1 (fr) 2009-06-04
EP2636404B1 (fr) 2019-03-20
CL2008003582A1 (es) 2009-04-03
EP2214480A4 (fr) 2010-09-29
AR069500A1 (es) 2010-01-27
US10307386B2 (en) 2019-06-04
EP2214480A1 (fr) 2010-08-11
HK1141945A1 (en) 2010-11-26
CN101932238A (zh) 2010-12-29
IL205909B (en) 2018-05-31
ES2417179T3 (es) 2013-08-06
TWI535435B (zh) 2016-06-01
JP5583022B2 (ja) 2014-09-03
IL254586A0 (en) 2017-11-30
JP6121951B2 (ja) 2017-04-26
TWI478710B (zh) 2015-04-01
MX2010005921A (es) 2010-06-11
PL2214480T3 (pl) 2013-11-29
AU2008329628B2 (en) 2014-06-26
US8263662B2 (en) 2012-09-11
EP2636404A2 (fr) 2013-09-11
RU2498795C2 (ru) 2013-11-20
EP2636404A3 (fr) 2013-10-16
US20120015005A1 (en) 2012-01-19
JP2017165735A (ja) 2017-09-21
US20100303870A1 (en) 2010-12-02
US20170304233A1 (en) 2017-10-26
NZ585732A (en) 2012-02-24
KR20100091219A (ko) 2010-08-18
CN101932238B (zh) 2015-04-08
JP2014237670A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
IL254586A0 (en) Methods for treating NASH using cystamine products
IL257681A (en) Methods and compositions for the treatment of cancer
PL3067054T3 (pl) Nowe kompozycje i sposoby leczenia nowotworów
HK1159498A1 (en) Methods and compositions for the treatment of cancer
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
ZA201006988B (en) Method and compositions for treatment of cancer
HK1129849A1 (en) Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP2049151A4 (fr) Méthodes et compositions pour le traitement du cancer
EP2340027A4 (fr) Procédés et compositions destinés au traitement du cancer
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
IL199689A0 (en) Compounds and method for treatment of cancer
EP2150270A4 (fr) Méthodes et compositions pour traiter le cancer
EP2225226A4 (fr) Composés et procédé pour le traitement du cancer
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
SI2214480T1 (sl) Postopki za zdravljenje nealkoholnega steatohepatitisa (NASH) z uporabo cisteaminskih proizvodov
IL196727A0 (en) Composition and method for treatment of tumors
EP2162021A4 (fr) Procédé de traitement alimentaire
EP2252298A4 (fr) Compositions et procédés pour le traitement du cancer du poumon
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
LT3067054T (lt) Naujos kompozicijos ir būdai vėžiui gydyti
EP2068629A4 (fr) Compositions et methodes de traitement du cancer